Reach Us +44-1904-929220
The Relationship Between Plasma Soluble Urokinase-type Plasminogen Activator Receptor And Pelvic Inflammatory Disease | 3621

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The relationship between plasma soluble urokinase-type plasminogen activator receptor and pelvic inflammatory disease

3rd International Conference on Biomarkers & Clinical Research

Hsiu-Ting Tsai, Po-Hui Wang and Shun-Fa Yang

Accepted Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.015

Objectives: The purpose of this study was to estimate the expressions of urokinase-type plasminogen activator (u-PA), soluble urokinase-type plasminogen activator receptor (su-PAR), plasminogen activator inhibitor-1 (PAI-1) in plasma, and the gene polymorphisms in patients with pelvic inflammatory disease (PID) and healthy controls. Methods: The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were respectively used to measure the plasma levels and polymorphisms of u-PA, u-PAR, and PAI-1 among seventy healthy controls and in Sixty-four PID patients before and after they received routine treatment protocols. Results: We found the level of plasma soluble u-PAR was significantly elevated in PID patients compared to that in normal controls and decreased significantly compared to that in same patients after they received treatment. The increased expression of u-PAR was significantly correlated with the cell counts of WBC in blood and the levels of plasma CRP as well as u-PA of PID patients before they received treatment, also, significantly correlation between plasma concentration of u-PA and u-PAI-1 was found among PID patients before they received treatment. There was no association between genetic polymorphisms and their gene expression levels and PID susceptibility. Conclusions: Elevated plasma u-PAR could be a biological marker for the diagnosis and to be a new strategy for target therapy of pelvic inflammatory disease.
Relevant Topics